A social media appeal by Hyderabad-based paediatrician Dr Sivaranjani Santosh has brought hope to seven children living with a rare genetic disorder, after an effort to secure an affordable supply of a medicine that was previously costing one family as much as Rs 12–13 lakh a month.
The initiative, undertaken with Access to Medicines India and the Netherlands-based Pharmaceutical Accountability Foundation (PAF), has helped arrange access to Tiratricol, a medicine used to treat Allan-Herndon-Dudley syndrome (AHDS), also known as MCT8 deficiency.
The intervention is expected to make treatment considerably more affordable for the seven children, whose families had struggled to access the medicine because of its prohibitive cost.
Dr Sivaranjani, a paediatrician with 18 years of experience, became involved after treating Arav, a 20-month-old boy diagnosed with the disorder. His mother, Pavitra Sirolkar, was faced with the daunting task of arranging Rs 12–13 lakh for a month's supply of the medicine imported from Germany. With treatment potentially required throughout his life, the expense was unsustainable.
According to reports, Dr Sivaranjani initially approached pharmaceutical companies and explored compassionate-use options to secure the drug but was unable to find a long-term solution.
She subsequently took the issue to social media, posting an appeal on September 7 to seek support for the affected children. The appeal reached PAF, which explored the possibility of preparing the medicine through a compounding arrangement.
Transvaal Pharmacy in The Hague eventually developed the formulation, paving the way for an affordable supply for the seven children.
PAF estimated that a year's treatment for all seven patients would cost around 14,200 euros, approximately Rs 15.08 lakh. Dr Sivaranjani mobilised around Rs 6.09 lakh in India, while the foundation arranged the remaining amount in the Netherlands.
Highlighting the financial challenges faced by families, Dr Sivaranjani told other media outlets, that even a monthly expense of Rs 20,000 could become difficult to sustain when treatment was required lifelong.
Allan-Herndon-Dudley syndrome is a rare genetic disorder that affects the transport of thyroid hormones into brain cells. Also known as MCT8 deficiency, the condition can result in severe neurological and developmental impairments.
Tiratricol is an analogue of the thyroid hormone T3. The US Food and Drug Administration has approved the drug, marketed as Emcitate, as the first treatment for symptoms associated with the disorder.
The children identified for the treatment are being cared for in two cities. According to ThePrint, five are under the supervision of Dr Praveen at Christian Medical College (CMC), Vellore, while the remaining two, including Arav, are being treated by Dr Sivaranjani.
The first batch of medicine is scheduled to be handed over to the parents of two children at Dr Sivaranjani's Hyderabad clinic on November 30. The other five families are expected to receive their supplies in Bengaluru.
However, the paediatrician believes that arranging medicines through international collaborations cannot be a permanent solution.
She has said that a medicine being available elsewhere in the world but remaining inaccessible to Indian children is a problem that needs to be addressed at the policy level.
Dr Sivaranjani plans to approach the Union government along with Access to Medicines India to explore the possibility of manufacturing the medicine domestically. She is also reaching out to doctors to identify more children with confirmed or suspected MCT8 deficiency.
Apart from her clinical practice, Dr Sivaranjani is known for using social media to promote preventive child healthcare, share information on newborn care and breastfeeding, and educate parents about first aid and CPR.
(As per media reports)